Where an SDHA pathogenic variant has been identified in tumour tissue, germline testing has been recommended by the European Society of Medical Oncology Precision Medicine Working Group.18 However, identification of an SDHA PGV in an individual with a non-SDHA-associated tumour could be considered a secondary or incidental finding. Here, SDHA is linked to neoplasm.